INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,406,916 | -12.9% | 2,239,742 | +15.5% | 0.00% | – |
| Q2 2023 | $10,803,906 | +317.9% | 1,939,660 | +329.9% | 0.00% | – |
| Q1 2023 | $2,585,335 | +477.7% | 451,193 | +5.9% | 0.00% | – |
| Q4 2022 | $447,535 | -61.0% | 426,224 | -0.5% | 0.00% | – |
| Q3 2022 | $1,148,000 | -44.1% | 428,431 | -0.5% | 0.00% | – |
| Q2 2022 | $2,054,000 | -42.8% | 430,520 | -51.0% | 0.00% | – |
| Q1 2022 | $3,593,000 | -37.1% | 878,400 | +4.9% | 0.00% | – |
| Q4 2021 | $5,708,000 | -45.3% | 836,998 | -7.1% | 0.00% | – |
| Q3 2021 | $10,439,000 | -31.9% | 900,719 | +0.1% | 0.00% | – |
| Q2 2021 | $15,335,000 | -10.1% | 899,873 | +4.4% | 0.00% | -100.0% |
| Q1 2021 | $17,061,000 | +31.1% | 861,683 | +36.6% | 0.00% | – |
| Q4 2020 | $13,018,000 | -1.1% | 630,751 | +25.9% | 0.00% | – |
| Q3 2020 | $13,169,000 | – | 500,934 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |